生物活性 | |||
---|---|---|---|
描述 | Ticlopidine is a selective and the first FDA-approved P2Y12 antagonist which can affect platelet aggregation when. It can be metabolized through cytochrome P450 in the liver and forms the active thienopyridine metabolites. The thienopyridine metabolites can irreversibly antagonize the P2Y12 receptor[3]. This results in inhibition of the binding of the P2Y12 agonist 2-methylthio-ADP and the ADP-induced downregulation of adenylyl cyclase[4]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00889044 | Platlet Aggregation ... 展开 >> Major Bleeding Outcomes 收起 << | Phase 3 | Unknown | June 2011 | Israel ... 展开 >> Sheba_medical_center Not yet recruiting Ramat-Gan, Israel Contact: Shlomo Matetzky, M.D 972-3-5302504 Shlomi.Matetzky@sheba.health.gov.il Sub-Investigator: Elad Asher, M.D Sheba Medical Center, Cardiac Institute Recruiting Tel Hashomer, Israel Contact: Shlomi Matetzky, MD 972-3-530-2504 shlomi.matetzky@sheba.health.gov.il Contact: Elad Asher, MD 972-3-530-2504 elad.asher@sheba.health.gov.il 收起 << |
NCT00853450 | Antiplatelet Effect | Phase 1 | Completed | - | Sweden ... 展开 >> Research Site Lund, Sweden 收起 << |
NCT00944333 | Angina Pectoris ... 展开 >> Silent Ischemia 收起 << | Phase 3 | Terminated(STOP due to recent ... 展开 >>data in literature questioning the need to continue DAP beyond six months in patients with stable coronary artery stenting with DES.) 收起 << | - | Italy ... 展开 >> Irccs Fondazione Centro S. Raffaele Del Monte Tabor - Milano (mi), Italy, 20132 收起 << |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.79mL 0.76mL 0.38mL |
18.95mL 3.79mL 1.90mL |
37.91mL 7.58mL 3.79mL |
参考文献 |
---|